STOCK TITAN

Vanguard Capital Management discloses 5.08% Cogent Biosciences (COGT) ownership in 13G filing

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Vanguard Capital Management LLC reports beneficial ownership of Cogent Biosciences Inc common stock on a Schedule 13G. Vanguard and certain affiliates report beneficial ownership of 8,691,589 shares, representing 5.08% of the outstanding common stock as of the reporting date.

Vanguard has sole voting power over 1,279,259 shares and sole dispositive power over 8,691,589 shares, with no shared voting or dispositive power. The position includes securities held by various Vanguard funds and managed accounts over which Vanguard entities exercise voting and/or dispositive authority, but no other individual person has an interest exceeding 5%.

Positive

  • None.

Negative

  • None.
Beneficial ownership 8,691,589 shares Amount of Cogent Biosciences common stock beneficially owned by Vanguard entities
Percent of class 5.08% Portion of Cogent Biosciences common stock class beneficially owned
Sole voting power 1,279,259 shares Shares over which Vanguard has sole power to vote or direct the vote
Shared voting power 0 shares Shares over which Vanguard has shared power to vote or direct the vote
Sole dispositive power 8,691,589 shares Shares over which Vanguard has sole power to dispose or direct disposition
Shared dispositive power 0 shares Shares over which Vanguard has shared power to dispose or direct disposition
Reporting date 06/30/2026 Date as of which ownership information is reported
beneficially owned financial
"this reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
dispositive power financial
"Sole Dispositive Power 8,691,589.00 8 | Shared Dispositive Power 0.00"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
Schedule 13G regulatory
"Vanguard Capital Management reports beneficial ownership on a Schedule 13G"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Investment Company Act of 1940 regulatory
"investment companies registered under the Investment Company Act of 1940 and other managed accounts"
A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.
percent of class financial
"Percent of class: 5.08 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What percentage of Cogent Biosciences (COGT) shares does Vanguard Capital Management report owning?

Vanguard Capital Management reports beneficial ownership of 5.08% of Cogent Biosciences’ common stock. This represents 8,691,589 shares, as disclosed in the Schedule 13G, and reflects holdings across various Vanguard funds and managed accounts under its discretionary control.

How many Cogent Biosciences (COGT) shares does Vanguard Capital Management beneficially own?

Vanguard Capital Management beneficially owns 8,691,589 shares of Cogent Biosciences common stock. These holdings are aggregated across specified Vanguard affiliates and business divisions where Vanguard exercises dispositive authority, representing 5.08% of the company’s outstanding common stock.

What voting power does Vanguard Capital Management have over Cogent Biosciences (COGT) shares?

Vanguard Capital Management has sole voting power over 1,279,259 shares of Cogent Biosciences common stock and no shared voting power. While Vanguard can dispose of 8,691,589 shares, it only directly controls the voting of a subset of that total.

What dispositive power does Vanguard Capital Management report for Cogent Biosciences (COGT)?

Vanguard Capital Management reports sole dispositive power over 8,691,589 shares of Cogent Biosciences common stock and no shared dispositive power. This means Vanguard-controlled entities can decide whether to sell or hold these shares without needing consent from another party.

Do other investors share in the Cogent Biosciences (COGT) holdings reported by Vanguard?

Vanguard states that affiliated funds and managed accounts have the right to receive dividends and sale proceeds from these Cogent shares. However, no single other person’s interest exceeds 5% of the Cogent Biosciences common stock class reported.

Which Vanguard entities are included in the Cogent Biosciences (COGT) Schedule 13G filing?

The filing attributes holdings to Vanguard Capital Management LLC and affiliates including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd, covering various funds and client accounts under their management.





19240Q201

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Capital Management
Signature:My Trieu-Gatt
Name/Title:Authorized Signatory, Head of Global Fund Administration
Date:07/31/2026